Home > Publications database > Soluble Receptor for Advanced Glycation End-products (sRAGE) and colorectal cancer risk: a case-control study nested within a European prospective cohort. > print

001     164096
005     20240229133512.0
024 7 _ |a 10.1158/1055-9965.EPI-20-0855
|2 doi
024 7 _ |a pmid:33082206
|2 pmid
024 7 _ |a 1055-9965
|2 ISSN
024 7 _ |a 1538-7755
|2 ISSN
024 7 _ |a altmetric:92803958
|2 altmetric
037 _ _ |a DKFZ-2020-02242
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Aglago, Elom Kouassivi
|0 0000-0002-0442-3284
|b 0
245 _ _ |a Soluble Receptor for Advanced Glycation End-products (sRAGE) and colorectal cancer risk: a case-control study nested within a European prospective cohort.
260 _ _ |a Philadelphia, Pa.
|c 2021
|b AACR
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1611325805_7173
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2021 Jan;30(1):182-192
520 _ _ |a Overexpression of the Receptor for Advanced Glycation End-product (RAGE) has been associated with chronic inflammation, which in turn has been associated with increased colorectal cancer (CRC) risk. Soluble RAGE (sRAGE) competes with RAGE to bind its ligands, thus potentially preventing RAGE-induced inflammation.To investigate whether sRAGE and related genetic variants are associated with CRC risk, we conducted a nested case-control study in the European Prospective Investigation into Cancer and Nutrition (EPIC). Plasma sRAGE concentrations were measured by ELISA in 1,361 CRC matched case-control sets. Twenty-four single nucleotide polymorphisms (SNPs) encoded in the genes associated with sRAGE concentrations were available for 1,985 CRC cases and 2,220 controls. Multivariable-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were computed using conditional and unconditional logistic regression for CRC risk and circulating sRAGE and SNPs, respectively.Higher sRAGE concentrations were inversely associated with CRC (ORQ5vs.Q1=0.77, 95%CI=0.59-1.00). Sex-specific analyses revealed that the observed inverse risk association was restricted to men (ORQ5vs.Q1=0.63, 95%CI=0.42-0.94) whereas no association was observed in women (ORQ5vs.Q1=1.00, 95%CI=0.68-1.48, Pheterogeneity for sex=0.006). Participants carrying minor allele of rs653765 (promoter region of ADAM10) had lower CRC risk (C vs. T, OR=0.90; 95%CI=0.82-0.99).Pre-diagnostic sRAGE concentrations were inversely associated with CRC risk in men but not in women. A SNP located within ADAM10 gene pertaining to RAGE shedding, was associated with CRC risk.Further studies are needed to confirm our observed sex difference in the association and better explore the potential involvement of genetic variants of sRAGE in CRC development.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|x 0
|f POF IV
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Rinaldi, Sabina
|b 1
700 1 _ |a Freisling, Heinz
|0 0000-0001-8648-4998
|b 2
700 1 _ |a Jiao, Li
|b 3
700 1 _ |a Hughes, David J
|0 0000-0003-1668-8770
|b 4
700 1 _ |a Fedirko, Veronika
|0 0000-0002-7805-9913
|b 5
700 1 _ |a Schalkwijk, Casper G
|b 6
700 1 _ |a Weiderpass, Elisabete
|0 0000-0003-2237-0128
|b 7
700 1 _ |a Dahm, Christina C
|0 0000-0003-0481-2893
|b 8
700 1 _ |a Overvad, Kim
|b 9
700 1 _ |a Eriksen, Anne Kirstine
|b 10
700 1 _ |a Kyrø, Cecilie
|0 0000-0002-9083-8960
|b 11
700 1 _ |a Boutron-Ruault, Marie-Christine
|0 0000-0002-5956-5693
|b 12
700 1 _ |a Rothwell, Joseph A
|0 0000-0002-6927-3360
|b 13
700 1 _ |a Severi, Gianluca
|0 0000-0001-7157-419X
|b 14
700 1 _ |a Katzke, Verena
|0 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
|b 15
|u dkfz
700 1 _ |a Kühn, Tilman
|0 P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe
|b 16
|u dkfz
700 1 _ |a Schulze, Matthias B
|0 0000-0002-0830-5277
|b 17
700 1 _ |a Aleksandrova, Krasimira
|b 18
700 1 _ |a Masala, Giovanna
|0 0000-0002-5758-9069
|b 19
700 1 _ |a Krogh, Vittorio
|0 0000-0003-0122-8624
|b 20
700 1 _ |a Panico, Salvatore
|b 21
700 1 _ |a Tumino, Rosario
|0 0000-0003-2666-414X
|b 22
700 1 _ |a Naccarati, Alessio
|0 0000-0001-5774-0905
|b 23
700 1 _ |a Bueno-de-Mesquita, Bas
|b 24
700 1 _ |a van Gils, Carla H
|b 25
700 1 _ |a Sandanger, Torkjel M
|b 26
700 1 _ |a Gram, Inger T
|0 0000-0002-0031-4152
|b 27
700 1 _ |a Skeie, Guri
|0 0000-0003-2476-4251
|b 28
700 1 _ |a Quirós, J Ramón
|b 29
700 1 _ |a Jakszyn, Paula
|b 30
700 1 _ |a Sánchez, Maria-Jose
|0 0000-0003-4817-0757
|b 31
700 1 _ |a Amiano, Pilar
|b 32
700 1 _ |a Huerta, José María
|0 0000-0002-9637-3869
|b 33
700 1 _ |a Ardanaz, Eva
|0 0000-0001-8434-2013
|b 34
700 1 _ |a Johansson, Ingegerd
|b 35
700 1 _ |a Harlid, Sophia
|0 0000-0001-8540-6891
|b 36
700 1 _ |a Perez-Cornago, Aurora
|0 0000-0002-5652-356X
|b 37
700 1 _ |a Mayén, Ana-Lucia
|0 0000-0001-9635-0416
|b 38
700 1 _ |a Cordova, Reynalda
|b 39
700 1 _ |a Gunter, Marc J
|b 40
700 1 _ |a Vineis, Paolo
|b 41
700 1 _ |a Cross, Amanda J
|0 0000-0002-0893-2377
|b 42
700 1 _ |a Riboli, Elio
|b 43
700 1 _ |a Jenab, Mazda
|b 44
773 _ _ |a 10.1158/1055-9965.EPI-20-0855
|g p. cebp.0855.2020 -
|0 PERI:(DE-600)2036781-8
|n 1
|p 182-192
|t Cancer epidemiology, biomarkers & prevention
|v 30
|y 2021
|x 1538-7755
909 C O |o oai:inrepo02.dkfz.de:164096
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe
913 0 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Cancer risk factors and prevention
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2020-01-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
|d 2020-01-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2020-01-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2020-01-17
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
|d 2020-01-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2020-01-17
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
|d 2020-01-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-01-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2020-01-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2020-01-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2020-01-17
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCER EPIDEM BIOMAR : 2018
|d 2020-01-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2020-01-17
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CANCER EPIDEM BIOMAR : 2018
|d 2020-01-17
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21